Integrated Filing — IndAS



General information about company

Scrip Code 532305
NSE Symbol INDSWFTLAB
MSEI Symbol NOTLISTED
ISIN INE915B01019
Name of company IND SWIFT LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 28-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 28-05-2026   17:00:00
End date and time of board meeting 28-05-2026   18:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 16,978.68 64,129.31
Other income 222.17 4,696.72
Total income 17,200.85 68,826.03
2 Expenses
(a) Cost of materials consumed 7,419.84 27,173.50
(b) Purchases of stock-in-trade 725.68 3,765.84
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,998.33) (2,694.22)
(d) Employee benefit expense 3,722.39 13,797.93
(e) Finance costs (243.47) 140.49
(f) Depreciation, depletion and amortisation expense 811.64 3,060.59
(f) Other Expenses
1 Other Expenses 5,052.16 17,576.55
Total other expenses 5,052.16 17,576.55
Total expenses 15,489.91 62,820.68
3 Total profit before exceptional items and tax 1,710.94 6,005.35
4 Exceptional items (515.24) (1,100.64)
5 Total profit before tax 1,195.70 4,904.71
6 Tax expense
7 Current tax 513.11 1,313.11
8 Deferred tax (828.00) (540.15)
9 Total tax expenses (314.89) 772.96
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,510.59 4,131.75
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.62 9.77
16 Total profit (loss) for period 1,511.21 4,141.52
17 Other comprehensive income net of taxes (87.45) (87.45)
18 Total Comprehensive Income for the period 1,423.76 4,054.07
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 8,683.66 8,683.66
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 1,38,402.35
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.81 4.95
Diluted earnings (loss) per share from continuing operations 1.76 4.84
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.81 4.95
Diluted earnings (loss) per share from continuing and discontinued operations 1.76 4.84
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: - 1. The above Audited Standalone and Consolidated Financial Results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 28th May, 2026. 2. The Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31.03.2026 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. 3. Figures of last quarter are the balancing figures between the published audited figures of the financial year, and the published figures for nine months ended 31st December, 2026 which were subjected to limited review by the statutory auditors. 4. The above Audited Standalone and Consolidated Financial Results are results of the combined entity post Amalgamation of Ind Swift Limited (ISL) with the Company. The Scheme of Amalgamation was sanctioned by the Hon’ble NCLT, Chandigarh Bench on 17th July, 2025 and the merger became effective from 8th August, 2025 (“Effective Date”). The Company issued and allotted a total of 81,24,698 (Eighty-One Lakhs Twenty-Four Thousand Six Hundred and Ninety-Eight) equity shares to the eligible shareholders of ISL on 25th August, 2025. The Company has given effect to the amalgamation of Ind-Swift Limited with the Company using the pooling of interest method as specified by Appendix C to Ind AS 103-“Business combination of entities under common control”. 5. Exceptional items for the quarter ended 31st March, 2026 comprise of Rs. 515.24 Lakhs and for the financial year ended 31st March, 2026 of Rs. 1100.64 Lakhs, towards balances written back/written off (net) on account of amounts no longer payable/receivable. 6. During the quarter ended 31st March 2026, 51,00,000 Warrants were converted into an equivalent number of equity shares upon receipt of the balance subscription amount. Consequently, as on 31st March 2026, a total of 1,95,00,000 Warrants had been converted into equity shares of the Company, out of the total 2,60,00,000 Warrants allotted by the Company. The balance 65,00,000 Warrants lapsed due to non-exercise of conversion right by the allottee. The upfront amount received on such Warrants has been forfeited in accordance with the terms of issue and applicable regulatory provisions. 7. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company. 8. The Company had made investment in the 800 Non-Convertible Debentures (NCD) of M/s. Ashok Investors Trust Ltd with the face value of Rs. 5,00,000/- each. Out of these 70 debentures have been redeemed till 31st March, 2026. 9. The Consolidated financial results include the financial results of the parent company, Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture: a) Ind-Swift Laboratories Inc., USA (Subsidiary) b) Fortune (India) Constructions Limited (Subsidiary) c) Indis Healthcare LLP (Joint Venture) d) MJM Remedies Private Limited (Subsidiary) e) ISLL Middle East LLC-FZ (Subsidiary) f) Ind Swift India Limited Kenya (Subsidiary) g) Capital Strikers LLP (Joint Venture) Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as ‘the Group’. 10. The Government of India has brought into force the new Labour Codes with effect from 21st November 2025, consolidating multiple existing labour legislations into a unified framework governing wages, social security, industrial relations and occupational safety. The Company has evaluated the implications of the said enactments on employee benefit obligations, particularly in relation to post-employment gratuity benefits and earned leave liabilities. Based on the assessment undertaken and actuarial valuation, the estimated impact has been recognized in the books of account during the current financial year and the same is not material to the results for the year. The Company shall continue to evaluate subsequent notifications, Rules and interpretative guidance issued in relation to the Labour Codes and revise the estimates, wherever required. 11. During the quarter under review the Company has not issued any Non-Convertible Debt Securities. 12. The previous period figures have been re-grouped and re-classified wherever necessary. 13. The Company is exclusively in the Pharmaceutical Business segment. Place: Chandigarh For Ind Swift Laboratories Limited Date: 28th March, 2026 N.R. Munjal Chairman



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 27,514.10
Capital work-in-progress 1,020.22
Investment property 220.74
Goodwill 0.00
Other intangible assets 2,524.59
Intangible assets under development 220.95
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 23,562.47
Trade receivables, non-current 0.00
Loans, non-current 7,354.40
Other non-current financial assets
1 other non -current financial assests 272.33
Total of other non-current financial assets 272.33
Total non-current financial assets 31,189.20
Deferred tax assets (net) 5,034.39
Other non-current assets
1 other non current assests 1,935.52
Total of other non-current assets 1,935.52
Total non-current assets 69,659.71
2 Current assets
Inventories 14,793.03
Current financial asset
Current investments 1,190.15
Trade receivables, current 19,854.58
Cash and cash equivalents 42,984.86
Bank balance other than cash and cash equivalents 0.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 3,010.60
Total current financial assets 67,040.19
Current tax assets (net)
Other current assets
1 Other current assets 15,842.05
Total of other current assets 15,842.05
Total current assets 97,675.27
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,67,334.98
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 8,683.66
Other equity 1,29,718.69
Total equity attributable to owners of parent 1,38,402.35
Non controlling interest (5.75)
Total equity 1,38,396.60
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,230.29
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 other non current financial liablities 258.94
Total of other non-current financial liabilities 258.94
Total non-current financial liabilities 1,489.23
Provisions, non-current 1,305.01
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1 other non current liablities 674.55
Total of other non-current liabilities 674.55
Total non-current liabilities 3,468.79
Current liabilities
Current financial liabilities
Borrowings, current 560.90
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 977.39
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 13,608.59
Total Trade payable 14,585.98
Other current financial liabilities
1 Other current financial liabilities 0.00
Total of other current financial liabilities 0.00
Total current financial liabilities 15,146.88
Other current liabilities 10,037.71
1 Other current liabilities 10,037.71
Total of other current liabilities 10,037.71
Provisions, current 277.96
Current tax liabilities (Net) 7.04
Deferred government grants, Current
Total current liabilities 25,469.59
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 28,938.38
Total equity and liabilites 1,67,334.98
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 87.45 87.45
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (87.45) (87.45)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 4,904.71
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories (3,375.40)
Adjustments for decrease (increase) in trade receivables, current (4,031.88)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (7,599.24)
Adjustments for decrease (increase) in other non-current assets 4,669.78
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 3,060.59
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss (142.02)
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (479.35)
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (5,529.80)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 2,204.86
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (11,222.46)
Net cash flows from (used in) operations (6,317.75)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (6,317.75)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 118.99
Purchase of property, plant and equipment 8,772.13
Proceeds from sales of investment property 0.00
Purchase of investment property 4,164.34
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 5,549.16
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (7,268.32)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 16,297.84
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 1,507.14
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 547.73
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (62.10)
Net cash flows from (used in) financing activities 14,180.87
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 594.80
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 548.85
Net increase (decrease) in cash and cash equivalents 1,143.65
Cash and cash equivalents cash flow statement at beginning of period 41,008.66
Cash and cash equivalents cash flow statement at end of period 42,152.31





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Rattan Kaur and Associates Yes 31-01-2027